Free tool
FAERS Monitor: Zusduri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215793 or its brand name (Zusduri, Mitomycin). Reports on generic versions are filed under their own applications.
Reports
2,955
Serious
2,453
83% of reports
Hospitalization
888
Death reported
379
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use364
- diarrhoea152
- nausea138
- dysuria112
- drug ineffective108
- thrombocytopenia107
- neutropenia106
- disease progression98
- pancytopenia93
- vomiting90
- fatigue89
- inappropriate schedule of product administration89
- rash83
- therapy interrupted80
- death77
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 67 |
| 2005 | 77 |
| 2006 | 86 |
| 2007 | 96 |
| 2008 | 125 |
| 2009 | 79 |
| 2010 | 94 |
| 2011 | 137 |
| 2012 | 134 |
| 2013 | 129 |
| 2014 | 86 |
| 2015 | 112 |
| 2016 | 97 |
| 2017 | 86 |
| 2018 | 127 |
| 2019 | 160 |
| 2020 | 152 |
| 2021 | 126 |
| 2022 | 89 |
| 2023 | 74 |
| 2024 | 132 |
| 2025 | 212 |
| 2026 | 478 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,204 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dysuriaSignal | 112 | 21.7 | 18.1 | 2,190 |
| pancytopeniaSignal | 93 | 11.9 | 9.7 | 915 |
| therapy interruptedSignal | 80 | 8.0 | 6.4 | 482 |
| thrombocytopeniaSignal | 107 | 6.8 | 5.7 | 528 |
| disease progressionSignal | 98 | 5.9 | 4.9 | 396 |
| neutropeniaSignal | 106 | 5.6 | 4.6 | 393 |
| inappropriate schedule of product administrationSignal | 89 | 3.5 | 2.9 | 159 |
| off label useSignal | 364 | 3.0 | 2.7 | 491 |
| diarrhoea | 152 | 1.7 | 1.4 | 42 |
| vomiting | 90 | 1.4 | 1.1 | 9 |
| rash | 83 | 1.4 | 1.1 | 8 |
| nausea | 138 | 1.2 | 1.1 | 6 |
| fatigue | 89 | 0.8 | 0.7 | 4 |
| death | 77 | 0.6 | 0.5 | 16 |
| drug ineffective | 108 | 0.6 | 0.5 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.